MMV371

Janssen
Asexual blood stages
Chemoprevention

MMV371

Translational
-
Preclinical
Product vision
  • Prophylaxis

MOA
  • Prodrug; active moiety is atovaquone (selective inhibitor of cytochrome bc1 complex)

Key features
  • Long acting injectable

  • Prodrug of well-tolerated, marketed prophylactic drug (atovaquone)

  • High liver-stage potency
Challenges
  • Cost and feasibility of formulation

Status
  • Preclinical development - Good Laboratory Practice intra-muscular safety studies complete

  • CMC - Good Manufacturing Practice drug product manufacture ongoing

Next milestone
  • Start of first-in-human phase I clinical study 2023
Previously
  • Discovery partnership between MMV and Calibr
  • Name: mCBE161
Project Director
  • Dr Andrew Slade